ASIT biotech’s Scientific Advisory Boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+™

The SAB, composed of international experts in the field of allergy immunotherapy, acknowledged the clinical benefits of gp-ASIT+™ and confirmed the interest of a follow-up study to enhance the future market positioning and differentiation of the compound.

Brussels, Belgium, March 29, 2019, 7:00 am (CET) – ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, today announced the positive outcomes and recommendations following the meetings of its scientific advisory boards, bringing together 9 of the most recognized international experts in the field of allergy immunotherapy.

Three topics were discussed by the experts:

  • the best positioning of gp-ASIT+™, the lead product candidate of the Company for grass pollen rhinitis currently evaluated in a confirmatory phase III study, within the context of existing therapeutic approaches,
  • a project of a second pollen season follow-up treatment of patients suffering from grass pollen allergy currently included in the gp-ASIT+™ Phase III trial (gpASIT011),
  • the Paediatric Investigational Plan to be proposed in view of the Marketing Authorization Application submission expected next year in Germany.

These very fruitful discussions led to:

  • acknowledging the benefit of gp-ASIT+™ as a fast acting short-course treatment compared to the currently available immunotherapy products,
  • confirming the interest of additional data on sustained or even improved effect of gp-ASIT+™ after an additional cycle of treatment preceding a second pollen season and to defining the optimal design of this follow-up study,
  • clarifying the optimal approach to address the challenges of paediatric development for innovative pre-seasonal short-course subcutaneous compounds.

The advices delivered during these two meetings held in March 2019 will support the ambitious clinical development program of ASIT biotech in grass pollen rhinitis. The results of the gpASIT011 study aiming to confirm the favourable benefit-risk ratio of gp-ASIT+™ are expected by the end of this year and will drive the market access strategy for this lead compound in this highly prevalent allergy.

Michel Baijot, CEO of ASIT biotech, commented: “I am happy that some of the most renowned European key opinion leaders in the field of allergy are supporting gp-ASIT+™ as the new therapeutic alternative with potential long-term benefits to patients with moderate to severe allergic rhinoconjunctivitis.”


***

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ - in ongoing phase III - and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and its facilities in Liège, Belgium.

ASIT biotech
Philippe Ghem
Phone nb.: +32 2 264 03 90
Email: investors@asitbiotech.com

NewCap
Dusan Oresansky / Pierre Laurent
Media and Investor Relations - France
Phone nb.: +33 1 44 71 94 92
Email: asitbiotech@newcap.eu

Comfi
Laure-Eve Monfort
Media Relations - Belgium
Phone nb.: +32 2 290 90 93
Email: monfort@comfi.be

 

Back to news